ETON — Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Achieved $24 million in product sales, a 73% increase year-over-year. This includes $3.3 million in licensing revenue from Q1 2025.
• Gross Profit: $14.7 million, up 49% from $9.9 million in the prior year. Adjusted gross profit was $16.2 million (67% of revenue).
• Adjusted EBITDA: $5.7 million, representing 24% of revenue, compared to $3.7 million (21% of revenue) in Q1 2025.
• Net Income: Reported net income of $1.6 million, compared to a net loss of $1.6 million in the prior year. Non-GAAP net income was $4.5 million.
• Cash Flow: Generated $7.4 million in cash flow from operations, with a cash balance of $19.7 million at quarter-end.

2. Strategic Updates and Business Highlights

• Product Launches: Successfully launched two major products, HEMANGEOL and DESMODA, expanding into pediatric dermatology and enhancing their rare disease portfolio.
• Portfolio Growth: Continued strong performance from existing products like INCRELEX, ALKINDI, and GALZIN, indicating a diversified and resilient product lineup.
• R&D Progress: Advanced several pipeline initiatives, including label harmonization for INCRELEX and ongoing studies for ET-700 and KHINDIVI, which could significantly expand market opportunities.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year revenue guidance to exceed $120 million, up from a previous estimate of $110 million, driven by strong Q1 performance and product launches.
• Adjusted EBITDA Margin: Expected to maintain a margin above 30% for the full year, with a long-term goal of reaching 50% by 2028.
• Growth Projections: Aiming for a $200 million annual revenue run rate by the end of 2027 and $500 million by 2030.

4. Bad News, Challenges, or Points of Concern

• Transition Challenges: The launch of HEMANGEOL involves transferring a large number of patients from multiple pharmacies to a single specialty pharmacy, which may lead to initial revenue limitations as the transition progresses.
• Market Competition: There is a risk of competition from off-label adult formulations of propranolol, which historically have been used for infantile hemangiomas, although Eton is addressing this through patient education and co-pay support.
• Regulatory Costs: Increased G&A expenses due to higher FDA fees, as Eton no longer qualifies for orphan PDUFA exemptions, which could impact profitability if not managed effectively.

5. Notable Q&A Insights

• Product Contribution: Analysts inquired about product-level contributions to revenue guidance, with HEMANGEOL expected to play a significant role.
• Patient Transition: Management emphasized the importance of a smooth transition for HEMANGEOL patients, with 60% of the patient base expected to be non-revenue-generating initially.
• Market Position: INCRELEX remains the largest product currently, with expectations for HEMANGEOL to potentially surpass it by 2027.
• Distribution Strategy: Eton is currently utilizing one specialty pharmacy for distribution, with plans to expand if necessary, but is pleased with current arrangements.

Overall, Eton Pharmaceuticals reported a strong start to 2026, with significant revenue growth and strategic advancements, while navigating challenges associated with product launches and market competition.